Mateon Therapeutics Inc. buy klostergang
Start price
03.06.15
/
50%
€1.36
Target price
07.12.15
€1.70
Performance (%)
-39.82%
End price
07.12.15
€0.82
Summary
This prediction ended on 07.12.15 with a price of €0.82. Massive losses of -39.82% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Mateon Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | 1.085% | -0.846% | 12.464% | 58.472% |
| iShares Nasdaq 100 | -1.665% | -3.306% | 1.502% | 84.473% |
| iShares Nikkei 225® | 3.863% | 6.308% | 22.272% | 56.185% |
| iShares S&P 500 | 0.111% | -1.337% | 1.101% | 58.320% |
Comments by klostergang for this prediction
In the thread Mateon Therapeutics Inc. diskutieren
Die FDA billigt PFS als primären Endpunkt der Phase-3-Studie :
http://seekingalpha.com/article/3228966-there-is-significant-upside-ahead-for-oxigene
(Vom Mitglied beendet)